Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study

the Australian and New Zealand Inflammatory Bowel Disease Consortium

Research output: Contribution to journal › Article › peer-review

36 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology